The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail


150 milligram(s) Solution for injection in pre-filled syringe

sanofi-aventis groupeEU/1/15/1031/010-012

Main Information

Trade NamePraluent
Active SubstancesAlirocumab
Strength150 milligram(s)
Dosage FormSolution for injection in pre-filled syringe
Licence Holdersanofi-aventis groupe
Licence NumberEU/1/15/1031/010-012

Group Information

ATC CodeC10AX Other lipid modifying agents
C10AX14 alirocumab


Licence Issued23/09/2015
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusUnknown


Summary of Product CharacteristicsSearch EMA website
Package LeafletSearch EMA website
Public Assessment ReportSearch EMA website
« Back